In vitro complement activation via nucleocapsid and spike proteins of SARS-CoV-2 in COVID-19 patients.

ABSTRACT: In the overactivation of the complement, the role of classical pathway is still not thoroughly investigated in COVID-19. Our aim was to examine the connection between SARS-CoV-2-specific antibodies, in vitro complement activation, and in vivo complement profiles in COVID-19 severity groups. Significant differences were detected in the in vitro complement deposition (C3b and C4b) between patients with or without SARS-CoV-2-specific antibodies in each COVID-19 severity group. Interestingly, we could detect in vitro complement depositions via nucleocapsid (N) protein without N-specific antibodies. Furthermore, no differences were detected in the levels of specific antibodies among the whole COVID-19 groups. In vitro complement activation by spike (S) protein was only detected with high S-spec

SUBMITTER: Kiszel P 

PROVIDER: S-EPMC12546619 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature